Status
Conditions
Treatments
Study type
Funder types
Identifiers
About
This study aims to compare real-world effectiveness of BRAF/MEK inhibitors in BRAF-mutant metastatic melanoma patients in the United States by line of therapy.
The Flatiron Health electronic health record (EHR) data from US cancer clinics will be used for this retrospective database analysis.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
-• Patients with prior BRAF- or MEK-inhibitor therapy
• Patients with ECOG performance status ≥ 2 (at the time of randomization for patients from COLUMBUS, during the baseline period for patients in Flatiron EHR)
1 participants in 3 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal